In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celldex Therapeutics Inc.

www.celldextherapeutics.com

Latest From Celldex Therapeutics Inc.

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Research & Development

Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin

Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.

Companies Research & Development

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Virus Research Institute Inc.
  • T Cell Sciences
  • Avant Immunotherapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celldex Therapeutics Inc.
  • Senior Management
  • Anthony S Marucci, Pres. & CEO
    Sam Martin, SVP, CFO
    Tibor Keler, PhD, EVP, CSO
    Ronald A Pepin, PhD, SVP, CBO
    Richard Wright, Chief Commercial Officer
    Diane C Young, MD, SVP, CMO
  • Contact Info
  • Celldex Therapeutics Inc.
    Phone: (908) 454-7120
    53 Frontage Rd.
    Ste. 220
    Hampton, NJ 08827
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register